These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23145809)

  • 1. Effect of laparoscopic splenectomy in patients with Hepatitis C and cirrhosis carrying IL28B minor genotype.
    Motomura T; Shirabe K; Furusyo N; Yoshizumi T; Ikegami T; Soejima Y; Akahoshi T; Tomikawa M; Fukuhara T; Hayashi J; Maehara Y
    BMC Gastroenterol; 2012 Nov; 12():158. PubMed ID: 23145809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C.
    Aizawa N; Enomoto H; Takashima T; Sakai Y; Iwata K; Ikeda N; Tanaka H; Iwata Y; Saito M; Imanishi H; Iijima H; Nishiguchi S
    J Gastroenterol; 2014 Aug; 49(8):1253-63. PubMed ID: 24065124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C.
    Cieśla A; Bociąga-Jasik M; Sobczyk-Krupiarz I; Głowacki MK; Owczarek D; Cibor D; Sanak M; Mach T
    World J Gastroenterol; 2012 Sep; 18(35):4892-7. PubMed ID: 23002361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
    Rallón NI; Soriano V; Naggie S; Restrepo C; Goldstein D; Vispo E; McHutchison J; Benito JM
    AIDS; 2011 May; 25(8):1025-33. PubMed ID: 21505315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.
    Matsuura K; Tanaka Y; Watanabe T; Fujiwara K; Orito E; Kurosaki M; Izumi N; Sakamoto N; Enomoto N; Yatsuhashi H; Kusakabe A; Shinkai N; Nojiri S; Joh T; Mizokami M
    J Viral Hepat; 2014 Jul; 21(7):466-74. PubMed ID: 24750345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.
    Younossi ZM; Birerdinc A; Estep M; Stepanova M; Afendy A; Baranova A
    J Transl Med; 2012 Feb; 10():25. PubMed ID: 22313623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.
    Miyamura T; Kanda T; Nakamoto S; Wu S; Jiang X; Arai M; Fujiwara K; Imazeki F; Yokosuka O
    Viruses; 2012 Aug; 4(8):1264-78. PubMed ID: 23012624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis.
    Ogawa E; Furusyo N; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Akahoshi T; Maehara Y; Hayashi J;
    J Gastroenterol Hepatol; 2014 Sep; 29(9):1728-35. PubMed ID: 24731162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia.
    Ogawa E; Furusyo N; Murata M; Ikezaki H; Ihara T; Hayashi T; Toyoda K; Okada K; Kainuma M; Kajiwara E; Takahashi K; Satoh T; Hayashi J
    J Viral Hepat; 2013 Dec; 20(12):838-46. PubMed ID: 24304453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.
    Dill MT; Duong FH; Vogt JE; Bibert S; Bochud PY; Terracciano L; Papassotiropoulos A; Roth V; Heim MH
    Gastroenterology; 2011 Mar; 140(3):1021-31. PubMed ID: 21111740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
    Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
    PLoS One; 2015; 10(9):e0137365. PubMed ID: 26339796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.
    Chen MY; Liu CH; Chen TC; Su TH; Chen PJ; Chen DS; Kao JH; Liu CJ
    J Gastroenterol Hepatol; 2014 Jan; 29(1):102-9. PubMed ID: 23829453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
    Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
    Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.
    Kurosaki M; Tanaka Y; Tanaka K; Suzuki Y; Hoshioka Y; Tamaki N; Kato T; Yasui Y; Hosokawa T; Ueda K; Tsuchiya K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Matsuura K; Sugauchi F; Enomoto N; Nishida N; Tokunaga K; Mizokami M; Izumi N
    Antivir Ther; 2011; 16(5):685-94. PubMed ID: 21817190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.
    Fukuhara T; Taketomi A; Motomura T; Okano S; Ninomiya A; Abe T; Uchiyama H; Soejima Y; Shirabe K; Matsuura Y; Maehara Y
    Gastroenterology; 2010 Nov; 139(5):1577-85, 1585.e1-3. PubMed ID: 20708617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of genes suppressing interferon effects in peripheral blood mononuclear cells during triple antiviral therapy for chronic hepatitis C.
    Iijima S; Matsuura K; Watanabe T; Onomoto K; Fujita T; Ito K; Iio E; Miyaki T; Fujiwara K; Shinkai N; Kusakabe A; Endo M; Nojiri S; Joh T; Tanaka Y
    PLoS One; 2015; 10(2):e0118000. PubMed ID: 25706116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.
    Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2012; 17(6):1059-67. PubMed ID: 22898703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.
    Boglione L; Cardellino CS; Cusato J; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
    Infect Genet Evol; 2017 Jul; 51():167-172. PubMed ID: 28315743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.